Racing Merck and Pfizer, Roche readies to file subcutaneous Tecentriq after posting phase 3 data

Roche has taken the lead in the race to bring subcutaneous checkpoint inhibitors to market in the West, reporting phase 3 results that tee it up to file for approval in the U.S. and the EU.